Three renal failure cases successfully treated with ombitasvir/paritaprevir/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation
We report three cases of genotype 1b hepatitis C virus (HCV) reinfection after liver transplantation. When antiviral treatment was considered, all three patients had renal dysfunction and had been treated with immunosuppressive agents for a long time; one with tacrolimus (TAC) and the others with cyclosporine A (CyA). Therefore, the possible antiviral regimens among direct-acting antivirals (DAA) were limited and so we treated all three patients with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r). Because ritonavir is known to markedly increase the blood concentration of TAC and CyA through drug–drug interactions, close monitoring of blood concentrations of TAC or CyA and dose adjustments of immunosuppressive agents were needed. Sustained virus response was achieved in all the patients treated, and there were no adverse effects or transplant rejection. OBV/PTV/r might be a useful DAA regimen for patients with genotype 1 HCV reinfection in the setting of renal dysfunction.
KeywordsOmbitasvir/paritaprevir/ritonavir Hepatitis C virus Liver transplantation Reinfection Direct-acting antiviral
This work was partially supported by the following grants: Grant-in-Aid for Scientific Research (KAKENHI) (C), (to Te.S., Grant ID 15K08492). We thank Mr. Steve Burke for his critical reading of the manuscript.
- 11.Yu ML, Chen YL, Huang CF, et al. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: real-world experience. J Formos Med Assoc. 2017. https://doi.org/10.1016/j.jfma.2017.06.006 (Epub ahead of print).Google Scholar
- 23.VIEKIRA PAK Highlights of Prescribing Information FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf. Accessed 29 Mar 2018.
- 25.GLE/PIB Highlights of Prescribing Information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209394s000lbl.pdf. Accessed 29 Mar 2018.
- 26.EBV plus GZR Highlights of Prescribing Information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208261s002lbl.pdf. Accessed 29 Mar 2018.